Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents-Reference-Cited by-同舟云学术

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

Published:2016-02-09 Issue:12 Volume:7 Page:14172-14187
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Takahashi Koichi¹²³,Patel Keyur⁴,Bueso-Ramos Carlos⁴,Zhang Jianhua²,Gumbs Curtis²,Jabbour Elias¹,Kadia Tapan¹,Andreff Michael¹,Konopleva Marina¹,DiNardo Courtney¹,Daver Naval¹,Cortes Jorge¹,Estrov Zeev¹,Futreal Andrew²,Kantarjian Hagop¹,Garcia-Manero Guillermo¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

4. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment;Laboratory Medicine;2024-07-13

3. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07

4. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study;The Lancet Haematology;2024-03

5. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms;Modern Pathology;2024-02